Resolution adopted by the extraordinary general meeting of Vitrolife

Resolution adopted by the extraordinary general meeting of Vitrolife

For purposes of Vitrolife's offer to the shareholders of MediCult, the general
meeting on 19 February 2009 resolved, in accordance with the board's proposal,
to authorise the board to issue new shares, to be paid for in kind, on one or
several occasions up to the next annual general meeting.




Queries should be addressed to: 
Magnus Nilsson, CEO, phone +46 31 721 80 61


________________________________________________________________________________
________________________________________________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. 
     The Fertility product area works with nutrient solutions (media),
cryopreservation products and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to evaluate and maintain organs
outside the body order to select usable organs and keeping them in optimal
condition while waiting for transplantation. The Stem Cell Cultivation product
area works with media and instruments to enable the use and handling of stem
cells for therapeutic purposes. 
     Vitrolife today has approximately 150 employees and the company's products
are sold in more than 80 markets. The company is headquartered in Gothenburg,
Sweden, and there are subsidiaries in USA, Australia, France and Italy.
Production facilities are located in Sweden and USA. 
     The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
________________________________________________________________________________
_________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com.
Website: www.vitrolife.com.

Vitrolife is required under the Swedish Securities Market Act to publish the
information in this press release. The information was submitted for publication
on 20 February 2009 at 8:00 am CET.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.